Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Pharma
Enhertu secures dual FDA approvals in early breast cancer
The FDA has simultaneously approved Enhertu for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Angus Liu
May 18, 2026 10:52am
Boehringer's Hernexeos earns FDA's 2nd national priority nod
Feb 26, 2026 3:22pm
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
FDA approves AZ/Daiichi's Enhertu in 1st-line breast cancer
Dec 15, 2025 4:15pm
Pfizer details Tukysa's 1st-line data in HER2 breast cancer
Dec 10, 2025 8:15am
FDA signs off on Bayer's HER2-mutated lung cancer med Hyrnuo
Nov 19, 2025 4:52pm
